Postmenopausal bleeding with a thickened endometrium and failed office biopsy
Margaret is 63 years old, para 2, and has had three episodes of light postmenopausal bleeding over the last two months. She has type 2 diabetes (HbA1c 8.1%), a BMI of 36 kg/m², and hypertension. She is not on HRT and has never used tamoxifen. Transvaginal ultrasound shows a retroverted uterus, endometrial thickness 9 mm, and an irregular hyperechoic area in the fundus; both ovaries are normal. Her cervical os is very stenotic and an office pipelle biopsy yields only scant tissue, reported as insufficient for diagnosis. She is anxious about cancer and asks whether a repeat scan in 3 months would be enough. She has a strong family history of colorectal cancer but no known Lynch syndrome. She is on metformin and ramipril.
1. What is the next step in investigation, and why is a repeat scan unacceptable?
Read the worked answer
Postmenopausal bleeding with an endometrial thickness of 9 mm and an irregular focal area requires tissue diagnosis. The accepted threshold for endometrial biopsy in PMB is around 4 mm; 9 mm is well above it, and her obesity, diabetes and hypertension increase the risk of endometrial hyperplasia or cancer. A repeat scan in 3 months would delay diagnosis and does not exclude a focal malignancy. Office pipelle sampling has a false-negative rate, especially with a focal lesion or a stenotic cervix, and the sample here is insufficient. The next step is hysteroscopy with directed biopsy and endometrial sampling, usually under general anaesthesia because the cervix is stenotic. Hysteroscopy allows direct visualisation of the irregular fundal area and targeted biopsy; blind sampling alone could miss the lesion. Arrange preoperative assessment, check haemoglobin, and counsel about the possibility of cancer. CA125 is not a diagnostic test for endometrial cancer and should not replace tissue biopsy.
2. How would you counsel her before hysteroscopy, and what are the limitations of the procedure?
Read the worked answer
Explain that hysteroscopy is the best way to see the cavity and obtain tissue, but it is a diagnostic procedure and may not be definitive if the cervix cannot be dilated or if the sample is inadequate. Consent for possible cervical dilatation, endometrial biopsy, polypectomy or resection, and for a second procedure if needed. Discuss risks: bleeding, infection, uterine perforation, cervical trauma, fluid overload from distension media, and, rarely, need for laparotomy. Anaesthetic risks are higher with obesity and diabetes, so involve anaesthesia early. Explain that if cancer is found, further imaging and staging will be arranged, and that hysteroscopy does not spread cancer. She should stop metformin if advised by the anaesthetist and follow local fasting guidance. Document that she understands a repeat procedure may be necessary if the cavity cannot be accessed.
3. If histology shows atypical endometrial hyperplasia, how would this change management?
Read the worked answer
Atypical endometrial hyperplasia is a premalignant lesion with a substantial risk of concurrent endometrial cancer, often quoted as up to 30–40%, and a high risk of progression. In a 63-year-old woman who is not seeking fertility, the standard treatment is total hysterectomy with bilateral salpingo-oophorectomy. Preoperative assessment should include anaesthetic review, imaging to assess adnexa, and counselling about the possibility of finding cancer at hysterectomy, which may require staging and lymph node assessment depending on grade and myometrial invasion. Progestin therapy is reserved for selected younger women who wish to preserve fertility or who are unfit for surgery, with repeat sampling. She should be referred to a gynaecological oncology multidisciplinary team. Address modifiable risk factors such as diabetes control and weight management, and explain that hysterectomy is curative for atypical hyperplasia but not a guarantee against cancer until histology is reviewed.